Renalytix (RNLX): PEG Multiple

Corporate company logo of renalytix.com (RNLX)

Renalytix Plc (RNLX) is creating a digital AI diagnostic environment by implementing KidneyIntelX for the early detection of renal pathologies. Clinic efficiency is supported by optimized express delivery of biomaterials, which prevents test spoilage. Stable demand for medtech renders the asset defensive, as confirmed by the peg_co ratio. The value of 0.00 reflects the latest metric reading, helping to determine the company's potential undervaluation relative to its growth rates.

renalytix.com (RNLX): PEG Multiple from 07/04/2022 to 10/19/2024

Analytical breakdowns for Renalytix Plc (RNLX)

- share price and consensus valuation forecast:
Price Performance Chart Renalytix|RNLX - Price Target Chart
- stock exchange capitalization data:
Market Capitalization Renalytix, plc|RNLX - Enterprise Value
- balance sheet equity data:
Net Assets per Share Renalytix|RNLX - Book Capitalization|Capitalization to Book Value Ratio renalytix.com|RNLX - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Equity Ratio Renalytix Plc|RNLX - Long-Term Debt to Capital|Current Liabilities to Capital Renalytix, plc|RNLX - Company Total Debt|Debts to Book Value Renalytix|RNLX - Company Long-Term Debt|Company Short-Term Loans and Borrowings Renalytix|Immediate Liquidity renalytix.com
- net income and valuation ratios data:
RNLX - Company Net Income|Net Profit Forecast Renalytix Plc|RNLX - P/E Multiple|Forward P/E Multiple renalytix.com|RNLX - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Renalytix plc|RNLX - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Renalytix|RNLX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months renalytix.com|RNLX - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Renalytix Plc
- issuer revenue and sales details:
RNLX - Company Sales|Company Revenue Forecast Renalytix AI|RNLX - Market Cap to Revenue|Forward Price to Sales Renalytix
Summary company analytics:RNLX - Renalytix Plc
Manufactured products of Renalytix, plc

The deployment of the KidneyIntelX AI platform, featuring proprietary kidney diagnostic algorithms, establishes a foundation for scaling profits through integration into insurance networks for Renalytix Plc (RNLX). By analyzing the historical PEG ratio, an investor compares market value with earnings growth: a ratio below one signals that the asset is undervalued relative to its expansion, confirming the fundamental capital stability of Renalytix Plc (RNLX).

Competitors of Renalytix Plc

TVTX (Travere Corp) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Ardelyx Corp ARDX|PEG Multiple ProKidney Corp. PROK|Akebia Therapeutics Inc - PEG Multiple|Growth-Adjusted Market Cap to Net Income Cara Therapeutics TVRD|DMAC: PEG Multiple|Growth-Adjusted P/E Ratio UNCY|Price/Earnings to Growth Ratio Rockwell Medical, Inc.|Growth-Adjusted P/E Ratio CVKD (Cadrenal Therapeutics)|Price/Earnings to Growth Multiple CDT (Conduit Therapeutics)|CALT - Price to Earnings Adjusted for Growth Rate|ZyVersa Therapeutics, Inc. - Price/Earnings to Growth Multiple